Key Considerations for the Only FDA-Approved oral TPO Receptor Agonist for the Treatment of Chronic ITP in Patients 1 year and Older

6:15–6:45 pm
Thursday, September 13
Corporate Showcase Presentations
While childhood immune thrombocytopenia (ITP) may spontaneously resolve, children who develop chronic ITP are often at significant risk for bleeding and may require treatment. In this program, we will present and discuss treatment options approved for use in pediatric patients with ITP. Objectives include:
  • Discuss the unique activity of an agent in the context of disease pathophysiology
  • Review efficacy and safety data
  • Review dosing and administration



Exhibit Hall Theater
Katie Atkinson, FNP
New York-Presbyterian Hospital
Weill Cornell Medical College